Voretigene neparvovec
Luxturna (voretigene neparvovec) is a gene pharmaceutical. Voretigene neparvovec was first approved as Luxturna on 2018-11-22. It has been approved in Europe to treat leber congenital amaurosis and retinitis pigmentosa.
| Trade Name | Luxturna |
|---|---|
| Common Name | Voretigene neparvovec |
| Indication | leber congenital amaurosis, retinitis pigmentosa |
| Drug Class |
